Table 1 Pharmacology properties and therapeutic benefits of MAOB inhibitors in clinical use for Parkinson's disease
From: Monoamine oxidase-B (MAO-B) inhibitors: implications for disease-modification in Parkinson’s disease
Selegiline | Rasagiline | |
|---|---|---|
Recommended dosage | 10 mg daily | 1 mg daily |
Bioavailability | Unknown [61] | 36% [62] |
Half-life | 10 hours [61] | 0.6 – 2 hours [62] |
Metabolite | L-amphetamine like metabolites [61] | Aminoindan [62] |
Symptomatic monotherapy | Efficacious [15] | |
Adjunct to levodopa and treatment to motor complications | Likely efficacious [15] | |
- Levodopa sparing effect | - Levodopa sparing effect | |
- Reduction in motor fluctuation | - Reduction in motor fluctuation | |
Disease-modification | Insufficient evidence | Insufficient evidence |